Eiger BioPharmaceuticals, Inc. (EIGRQ)
- Previous Close
2.2725 - Open
2.2100 - Bid --
- Ask --
- Day's Range
2.0500 - 2.2500 - 52 Week Range
1.1000 - 43.3500 - Volume
15,118 - Avg. Volume
124,422 - Market Cap (intraday)
3.332M - Beta (5Y Monthly) 2.01
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 14, 2024 - May 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.00
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.
www.eigerbio.comRecent News: EIGRQ
Performance Overview: EIGRQ
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EIGRQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EIGRQ
Valuation Measures
Market Cap
3.37M
Enterprise Value
19.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.21
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-56.45%
Return on Equity (ttm)
-367.00%
Revenue (ttm)
15.77M
Net Income Avi to Common (ttm)
-74.96M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
25.84M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-53.26M
Research Analysis: EIGRQ
Company Insights: EIGRQ
EIGRQ does not have Company Insights